Zoledronic acid
Antiproliferative and apopototic effects / Potent inhibitor of bone resorption (IC50 = 2 nM in mouse calvarial cultures).1 The mechanism of its action is thought to be via inhibition of osteoclastic activity, induction of osteoclast apoptosis and blockage of osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Clinically useful drug for treatment of osteoporosis2, hypercalcemia of malignancy(HCM), multiple myeloma and bone metastases from solid tumors3. It has also been investigated as an antitumor agent and showing efficacy as an adjuvant therapy in several cancers.4,5
Biochemicals & reagents
118072-93-8
CGP 42446; Zoledronate
1) Green et al. (1994), Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound J. Bone Miner.Res. 9 745 2) Deeks and Perry (2008) Zoledronic acid: a review of its use in the treatment of osteoporosis Drugs Aging 25 963 3) Perry and Figgitt (2004), Zoledronic acid: a review of its use in patients with advanced cancer Drugs 64 1197 4) Koto et al. (2010) Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis and shows combined effects with other anticancer agents Oncol.Rep. 24 233 5) Tonyali et al. (2010) The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives Expert Opin.Pharmacother. 11 2715
-20°C
PATHWAY: Apoptosis inducer; Posttranslational modification; Proliferation; NFkappaB; Cholesterol metabolism -- RESEARCH AREA: Cell death; Stem cells; Angiogenesis -- DISEASE AREA: Cancer; Osteoporosis